This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global liquid biopsy for cancer diagnostics market reached a value of nearly $9.22 billion in 2024, having grown at a compound annual growth rate (CAGR) of 15.72% since 2019. The market is expected to grow from $9.22 billion in 2024 to $19.81 billion in 2029 at a rate of 16.52%. The market is then expected to grow at a CAGR of 16.20% from 2029 and reach $41.97 billion in 2034.
Growth in the historic period resulted from the rising demand for personalized medicine, rise in healthcare expenditure, increasing number of clinical trials and government initiatives for research and development in healthcare. Factors that negatively affected growth in the historic period was limited reimbursement policies.
Going forward, the increasing cancer prevalence, growing aging population and growing cancer research investments will drive the growth. Factor that could hinder the growth of the liquid biopsy for cancer diagnostics market in the future include lack of trained personnel and high cost of technology.
The global liquid biopsy for cancer diagnostics market is fairly fragmented, with a large number of small players in the market. The top ten competitors in the market made up 24.44% of the total market in 2023. F. Hoffmann-La Roche AG was the largest competitor with a 4.95% share of the market, followed by Thermo Fisher Scientific Inc. with 3.17%, Guardant Health Inc. with 3.11%, Illumina Inc. with 2.87%, Exact Sciences Corporation with 2.20%, Natera Inc. with 2.07%, Johnson & Johnson Services Inc. with 1.93X%, Bio-Rad Laboratories Inc. with 1.90%, Caris Life Science with 1.19% and Sysmex Corporation with 1.06%.
The liquid biopsy for cancer diagnostics market is segmented by type into product and services. The product market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by type, accounting for 72.93% or $6.72 billion of the total in 2024. Going forward, the services segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by type, at a CAGR of 17.90% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by cancer into lung cancer, breast cancer, colon cancer and other cancers. The lung cancer market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by cancer, accounting for 32.67% or $3.01 billion of the total in 2024. Going forward, the lung cancer segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by cancer, at a CAGR of 18.99% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by sample into blood, urine and saliva. The blood market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by sample, accounting for 79.82% or $7.36 billion of the total in 2024. Going forward, the urine segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by sample, at a CAGR of 18.84% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by end user into hospitals, diagnostic centers and other end users. The hospitals market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by end user, accounting for 55.83% or $5.15 billion of the total in 2024. Going forward, the diagnostic centers segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by end user, at a CAGR of 19.95% during 2024-2029.
North America was the largest region in the liquid biopsy for cancer diagnostics market, accounting for 47.21% or $4.35 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the liquid biopsy for cancer diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 18.06% and 17.14% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 16.37% and 14.04% respectively.
The top opportunities in the liquid biopsy for cancer diagnostics market segmented by type will arise in the product segment, which will gain $7.39 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by cancer will arise in the lung cancer segment, which will gain $4.17 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by end user will arise in the hospitals segment, which will gain $5.16 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by sample will arise in the blood segment, which will gain $8.22 billion of global annual sales by 2029. The liquid biopsy for cancer diagnostics market size will gain the most in the USA at $4.28 billion.
Market-trend-based strategies for the liquid biopsy for cancer diagnostics market include focus on developing high-precision liquid biopsy for identifying cancer biomarkers, focus on revolutionizing next-generation automated liquid biopsy technologies for oncology and prenatal care, focus on developing next-generation liquid biopsy tools that improve cancer screening capabilities and focus on next-generation liquid biopsy tests to enhance personalized cancer treatment plans.
Player-adopted strategies in the liquid biopsy for cancer diagnostics market include focus on enhancing operational capabilities through strategic partnerships, focus on expanding business expertise through new launches focus on improving portfolio and strengthening its business through strategic acquisitions.
To take advantage of the opportunities, the analyst recommends the liquid biopsy for cancer diagnostics companies to focus on developing high-precision liquid biopsy solutions, focus on advancing automated liquid biopsy technologies, focus on advancing next-generation tools for enhanced cancer screening, focus on advancing next-generation liquid biopsy solutions, focus on enhancing tumor detection and profiling in liquid biopsy, expand in emerging markets, focus on expanding distribution channels for liquid biopsy solutions, focus on developing competitive and accessible pricing strategies, focus on building awareness through targeted educational campaigns, focus on strengthening digital and social media marketing and focus on targeting hospitals and diagnostic centers for enhanced market penetration.
The global liquid biopsy for cancer diagnostics market reached a value of nearly $9.22 billion in 2024, having grown at a compound annual growth rate (CAGR) of 15.72% since 2019. The market is expected to grow from $9.22 billion in 2024 to $19.81 billion in 2029 at a rate of 16.52%. The market is then expected to grow at a CAGR of 16.20% from 2029 and reach $41.97 billion in 2034.
Growth in the historic period resulted from the rising demand for personalized medicine, rise in healthcare expenditure, increasing number of clinical trials and government initiatives for research and development in healthcare. Factors that negatively affected growth in the historic period was limited reimbursement policies.
Going forward, the increasing cancer prevalence, growing aging population and growing cancer research investments will drive the growth. Factor that could hinder the growth of the liquid biopsy for cancer diagnostics market in the future include lack of trained personnel and high cost of technology.
The global liquid biopsy for cancer diagnostics market is fairly fragmented, with a large number of small players in the market. The top ten competitors in the market made up 24.44% of the total market in 2023. F. Hoffmann-La Roche AG was the largest competitor with a 4.95% share of the market, followed by Thermo Fisher Scientific Inc. with 3.17%, Guardant Health Inc. with 3.11%, Illumina Inc. with 2.87%, Exact Sciences Corporation with 2.20%, Natera Inc. with 2.07%, Johnson & Johnson Services Inc. with 1.93X%, Bio-Rad Laboratories Inc. with 1.90%, Caris Life Science with 1.19% and Sysmex Corporation with 1.06%.
The liquid biopsy for cancer diagnostics market is segmented by type into product and services. The product market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by type, accounting for 72.93% or $6.72 billion of the total in 2024. Going forward, the services segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by type, at a CAGR of 17.90% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by cancer into lung cancer, breast cancer, colon cancer and other cancers. The lung cancer market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by cancer, accounting for 32.67% or $3.01 billion of the total in 2024. Going forward, the lung cancer segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by cancer, at a CAGR of 18.99% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by sample into blood, urine and saliva. The blood market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by sample, accounting for 79.82% or $7.36 billion of the total in 2024. Going forward, the urine segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by sample, at a CAGR of 18.84% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by end user into hospitals, diagnostic centers and other end users. The hospitals market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by end user, accounting for 55.83% or $5.15 billion of the total in 2024. Going forward, the diagnostic centers segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by end user, at a CAGR of 19.95% during 2024-2029.
North America was the largest region in the liquid biopsy for cancer diagnostics market, accounting for 47.21% or $4.35 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the liquid biopsy for cancer diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 18.06% and 17.14% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 16.37% and 14.04% respectively.
The top opportunities in the liquid biopsy for cancer diagnostics market segmented by type will arise in the product segment, which will gain $7.39 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by cancer will arise in the lung cancer segment, which will gain $4.17 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by end user will arise in the hospitals segment, which will gain $5.16 billion of global annual sales by 2029. The top opportunities in the liquid biopsy for cancer diagnostics market segmented by sample will arise in the blood segment, which will gain $8.22 billion of global annual sales by 2029. The liquid biopsy for cancer diagnostics market size will gain the most in the USA at $4.28 billion.
Market-trend-based strategies for the liquid biopsy for cancer diagnostics market include focus on developing high-precision liquid biopsy for identifying cancer biomarkers, focus on revolutionizing next-generation automated liquid biopsy technologies for oncology and prenatal care, focus on developing next-generation liquid biopsy tools that improve cancer screening capabilities and focus on next-generation liquid biopsy tests to enhance personalized cancer treatment plans.
Player-adopted strategies in the liquid biopsy for cancer diagnostics market include focus on enhancing operational capabilities through strategic partnerships, focus on expanding business expertise through new launches focus on improving portfolio and strengthening its business through strategic acquisitions.
To take advantage of the opportunities, the analyst recommends the liquid biopsy for cancer diagnostics companies to focus on developing high-precision liquid biopsy solutions, focus on advancing automated liquid biopsy technologies, focus on advancing next-generation tools for enhanced cancer screening, focus on advancing next-generation liquid biopsy solutions, focus on enhancing tumor detection and profiling in liquid biopsy, expand in emerging markets, focus on expanding distribution channels for liquid biopsy solutions, focus on developing competitive and accessible pricing strategies, focus on building awareness through targeted educational campaigns, focus on strengthening digital and social media marketing and focus on targeting hospitals and diagnostic centers for enhanced market penetration.
Major Market Trends
- High-Precision Liquid Biopsy for Identifying Cancer Biomarkers
- Advancements in Automated Liquid Biopsy Technologies for Oncology and Prenatal Care
- Next-Generation Liquid Biopsy Tool Improves Cancer Screening Capabilities
- Technological Advancement in Liquid Biopsy for Personalized Cancer Treatment
- Enhancing Tumor Detection and Profiling With Liquid Biopsy
Key Mergers and Acquisitions
- Quest Diagnostics Acquired Haystack Oncology
- Exact Sciences Corporation Acquired Resolution Bioscience, Inc.
- Exact Sciences Corporation Acquired Thrive Earlier Detection
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Liquid Biopsy for Cancer Diagnostics Market - Macro-Economic Scenario
9 Global Market Size and Growth
10 Global Liquid Biopsy for Cancer Diagnostics Market Segmentation
11 Liquid Biopsy for Cancer Diagnostics Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Other Major and Innovative Companies
23 Key Mergers and Acquisitions
24 Opportunities and Strategies
25 Liquid Biopsy for Cancer Diagnostics Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Liquid Biopsy For Cancer Diagnostics Global Market Opportunities and Strategies to 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global liquid biopsy for cancer diagnostics market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for liquid biopsy for cancer diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The liquid biopsy for cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider liquid biopsy for cancer diagnostics market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by cancer, by sample and by end user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - the report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the liquid biopsy for cancer diagnostics market.
- Global Market Size and Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by cancer, by end user and by sample in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies - Details on the company profiles of other major and innovative companies in the market
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for liquid biopsy for cancer diagnostics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) by Type: Product; Services2) by Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
3)by Sample: Blood; Urine; Saliva
4) by End User: Hospitals; Diagnostic Centers; Other End Users
Key Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Guardant Health Inc.; Illumina Inc.; Exact Sciences Corporation
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; liquid biopsy for cancer diagnostics indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
Some of the major companies featured in this Liquid Biopsy for Cancer Diagnostics market report include:- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Guardant Health Inc.
- Illumina Inc.
- Exact Sciences Corporation
- Natera Inc.
- Johnson & Johnson Services Inc.
- Bio-Rad Laboratories Inc.
- Caris Life Science
- Sysmex Corporation
- Strand Life Sciences
- Adicon Holdings Limited
- SOPHiA GENETICS SA
- QIAGEN N. V.
- Novigenix
- Roche Diagnostics Polska Sp. z o.o.
- Janssen Diagnostics LLC
- Twist Bioscience
- Biocept
- BioMark Diagnostics Inc.
- GRAIL, Inc.
- Foundation Medicine, Inc.
- GeneCentric Therapeutics Inc.
- DGLAB
- Oncoclínicas Group
- Grupo Fleury
- Detectiome
- Anwa Medical Company
- Syndicate Bio
- PathCare
- Axaitech
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 262 |
| Published | February 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 9.22 Billion |
| Forecasted Market Value ( USD | $ 41.97 Billion |
| Compound Annual Growth Rate | 16.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
